Tetracycline is a polyketide antibiotic produced by the actinobacteria genus Streptomyces. Since chlortetracycline was first described in 1945, the tetracycline antibiotic family has been used successfully to treat everything from cholera to acne. Over time, however, some bacteria have developed a specific resistance to tetracycline.

Tet Repressor Protein (TetR) confers resistance to the tetracycline family of antibiotics. In certain bacteria, TetR is weakly expressed until exposure to a tetracycline compound triggers the up-regulation of a TetR positive feedback mechanism. TetR has also been implicated as a transcription regulator.

Novus has recently released two new TetR antibodies for research on transcription regulation or bacterial Tet resistance. NB600-234 is directed to an internal region of TetR, while NBP1-78424 is directed to the N-terminal region. Both antibodies have been thoroughly characterized in Western blot on recombinant TetR protein, however we also offer an Innovator’s Reward™ Program for testing new applications.